The purpose of this study was to evaluate in a double-blind placebo-based study the effects of fiuoxetine over a period of 16 weeks on the frequency of binging and purging and on fiuctuations in the levels of cariogenic organistns and saliva secretion rate of patients (/; = 30) with bulima nervosa. Profile analysis suggested that, over the course of the study, binging and purging frequency and Streptococcus sobrinus salivary levels decreased significantly in the fiuoxetine group as cotnpared with the plaeebo group. Our finding that 5. sohrinus levels decreased 16 weeks after subjects were on medication suggests that the salivary levels of these organistns could serve as an objectively measured indicator of patient compliance with antibulimic therapy.
Fiuoxetine is a specific blocker of serotonin reuptake (12) that has been used to decrease binge-eating and vomiting in patients with bulimia nervosa (6-8, 1 1). We have previously reported (4) that Streptococcus .sobrinus appears to be an indicator of bulimic behavior (active binging and purging). The purpose of the present study was to evaluate in a double-blind placebo-based study the effects of fiuoxetine over a period of 16 weeks on the frequency of binging and purging, on fiuctuations in the levels of cat'iogenic organisms and on the rate of saliva secretion of patients with bulimia nervosa.
This investigation was perfortned on a subset of subjects who participated in a tnulticentet, double-blind, placebocontrolled study of the efficacy and safety of fiuoxetine. Approxitnately 400 patients at 15 different sites comprised tlte trial study group. The multicenter protocol included a 1-week, no-therapy screenitig period and a 2-week, singleblind placebo lead-in period. The study subjects at the University of Michigan site comprised 30 patients (29 women and 1 man), 23 randomized to fiuoxetine treatment and 7 to placebo treatment. Patients frotn both groups were well matched on age, age of onset of bulitnic behavior, height and weight. The patients received 60 mg orally each day, over a course of 16 weeks. Cotnpliance was assessed by pill counts performed at each visit. Assessment of frequency of binging and purging and of oral microbial and salivary parameters were performed at the end of the 2-week, single-blind plaeebo period (baseline); after 8 weeks on active drug or placebo; and after 16 weeks on active drug or placebo.
In order to be included in the study, patients must have reported binge-eating and votniting at least 3 times per week for at least 6 months and had to meet all DSM-III-R (3) criteria for bulitnia nervosa. Symptoms must not have decreased markedly during the placebo lead-in period. Binging and vomiting frequencies were assessed by a patient diary that was collected at each visit. We developed a scale in order to rate bingepurge severity: 1: < than once a week; 2: once a week; 3; twice a week; 4: 3 times a week; 5:4 to 6 titnes a week; 6: > 7 titnes a week. This scale was developed to refiect changes in behavior that might be particularly relevant to changes in the oral fiora of the patients.
Paraffin-stimulated whole saliva was collected from subjects for 5 min from which the saliva secretion rate was detertnined (ml/min). The levels of eariogenie organisms were assessed as previously described (4). Briefiy, 1 tnl of saliva was serially diluted at the ratios of 1:10, 1:100 and 1:1000 in reduced transport fiuid and plated on selective media by tneans of a spiral plating system. TYCSB mediutn for Streptococcus ntutans and S. sobrinus (15), LBS agar for lactobacilli (13) , and Saboraud dextrose agar (SAB) for yeasts were employed as selective media for these orgatiistns. The number of colony-fonning units (CFU)/ml of saliva was calculated after 2 to 3 days of anaetobic incubation (TYCSB and LBS) and aerobic incubation (SAB), S. tmttans and 5. sobrintts were distinguished by colony tnorphology. Representative colonies of these organisms from each plate were submitted to a biochemical scheme for the identification of the mutans streptococci proposed by Shklair & Keene (14) . Organisms growing on the TYCSB medium other than S. mutans and S. ,sohrintts were found in M' Mi of the plates (10 of 74).
The effects of lluoxetine or placebo on microbial and salivary parameters after 8 weeks and 16 weeks on medication were evaluated (Table I) . None of the microbial parameters differed significantly between fiuoxetine and placebo groups. This may have been due to patient attrition resultitig in a stnall sample size or to the stnall size of the placebo group as dictated by the study designers. Another possible explanation is related to the reported frequency of binging and purging. This study has shown that subjects from both groups were to a certain extent still binging and purging at the end ol' the study" period, which could contribute to the persistence of aciduric organistns such as the mutans streptococci, lactobacilli and yeasts. The finding of no significant differences between groups in tenns of the levels of aciduric organisms may therefore refiect that the selection pressure for aciduric organistns had not been eliminated by fiuoxetine intake. The salivary levels of S. .sobrintts, however, significantly decreased at the 16-week visit in the fiuoxetine group (Table I) . Wtthtn the fiuoxetine group, the saliva secretion rate was significantly decreased after 8 weeks, a finding that seetns to have persisted into the 16th week of the study ( Table 1 ). The fact that the saliva secretion rate tneasured objectively significantly decreased in the subjects receiving fiuoxetine is an interesting finding, as virtually no studies have assessed the rate of saliva secretion objectively before and after the use of antidepressants. Parotid enlargement with dysfunction has been observed among bulimics due to votniting (1, 10) . Certain conditions are associated with parotid enlargement, such as work hypertroplty and electrolyte imbalance, which may result in decreased salivary function. Indeed, correlations between parotid enlargement and xerostomia were observed in bulimics (2) . Thus, the objective measuiement of a decrease in saliva secretion rate over the course of this study in the treattnent group could be a result of fiuoxetine usage, a result of parotid dysfunction or a combination of both.
The data from subjects who cotnpleted all phases of the study were analyzed by repeated-tneasures analysis of variance (profile analysis). Fifteen subjects in the fiuoxetine group and 5 subjects in the placebo group had cotnplete data. Profile analysis indicated that the average category frequency of binging (P = 0^0007) and purgitig (P = 0.0009) decreased over the course of this study in the fiuoxetine group cotnpared with the placebo group, i.e., frotn an average of at least daily binge-purge episodes to an average of twice a week (data not shown). These results are supported by the combined results frotn all of the investigative sites of the lluoxetine multicenter study (unpublished data), which showed that, after 16 weeks, fiuoxetine compared with placebo significantly reduced the average category frequency of bingitig and purging (> 50% decrease in vomiting or binge-eating episodes).
Profile analysis showed a decrease in S. .sohrintts salivary levels (P = 0.016) over the course of the study in the fiuoxetine group compared with the placebo group (Fig. I) , regardless of the stnall number of subjects in each group. A possible explanation for the decrease of S. .sobrimts in the fiuoxetine group is that S. sohrinus is more dependent than 5". mtttans lor sucrose-mediated attachtnent to the tooth enamel pellicle (10).
Accordingly, a decrease in the frequency of sugar itigestion (decrease iti the frequency of binging) would tiot favor its colonization. It was recently detnonstrated that S. sobrinus is capable of producing acid at low pH values, whereas other mutans streptococci species ceased acid productioti at sitnilar pH values (5) . Frotn these studies, we may postulate that S. .sobrinus tnay be highly active in acidic environments refiecting current etnetic activity, as iti the case of bulimic subjects, and that after bulitnic episodes (purging) are reduced, a decrease in the levels of 5. .sobrinus may occur.
Our finding that S. .sobrimts salivary levels were decreased 16 weeks after subjects were on tnedication suggests that the salivaty levels of these organistns eould serve as an objectively tneasured indicator of patient compliance with antibulitnic therapy. This is in agreetnent with our previous observation that, in untreated bulitnic individuals, tlte salivary levels of 5. .sobrinus were elevated relative to a healthy matched control group (4). The finding that S. sobrinus could be used to monitor bulimic behavior needs to be reproduced in larger population-based studies. It would be of interest to eonduct future studies with the use of tnore accurate assays for the enumeration of S. .sobrinus such as monoclonal antibodies and DNA probes.
